Given that only a few preclinical compounds inhibiting the MCM2–7 complex’s enzymatic activity and/or expression have been discovered48, and no FDA-approved drugs have been reported to target MCM complex, it is meaningful that we found ATO, approved in clinics, could target MCM7 in HCC. This evidence concerns the gene MCM2 and hepatocellular carcinoma.